Approval and release of abiraterone acetate for Stage IV Prostate Cancer
- Target:
- United States Congress
- Region:
- United States of America
Based on clinical trial results to date, patients have experienced confirmed declines in prostate specific antigen (PSA) levels of up to 90+%, partial radiological responses (as measured by the RECIST criteria), regressing bone disease, improvement in pain and reduced opioid use.
The compound has been well tolerated with minimal toxicity and no dose limiting toxicity has been observed.
This petition of United States citizens, who are friends, family or supporters of sufferers of Stage IV metastatic prostate cancer, which is the second leading cause of cancer death in American men draws to the attention of the United States Congress the need to expedite the approval and release of abiraterone acetate, the treatment associated with pronounced tumor shrinkage and a fall in prostate specific antigen (PSA) levels in 70–80% of patients, by the United States Food and Drug Administration.
The latest American Cancer Society estimates for prostate cancer in the United States are for 2009:
• about 192, 280 new cases of prostate cancer will be diagnosed (1 in 6 men)
• 27,360 men will die of prostate cancer (1 in 35 men)
Stage IV metastatic prostate cancer is considered untreatable cancer. We therefore ask the United States Congress to introduce and pass any legislation or to take any administrative action available to the Congress that will enable sufferers of Stage IV metastatic prostate cancer to urgently receive breakthrough life saving treatment for this very fatal disease.
You can further help this campaign by sponsoring it
The Approval and release of abiraterone acetate for Stage IV Prostate Cancer petition to United States Congress was written by Candace Kelly and is in the category Health at GoPetition.